Elite Pharmaceuticals Appoints Davis S. Caskey to Its Board of Directors
04 mai 2016 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., May 04, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) announced today that its Board of Directors has appointed Davis S. Caskey to...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Third Quarter of Fiscal Year 2016
09 févr. 2016 16h31 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 09, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended December 31, 2015, the third quarter...
Elite Pharmaceuticals, Inc. Reports Strong Growth for Second Quarter of Fiscal Year 2016
09 nov. 2015 16h37 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Nov. 09, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP), announced results for the quarter ended September 30, 2015, the second...
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200
21 oct. 2015 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced positive top-line results from the Phase 3 pivotal trial of...
Elite Pharmaceuticals, Inc. to Host Conference Call and Webcast to Discuss 1st Quarter 2016 Financial Results on August 11, 2015
06 août 2015 08h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Aug. 6, 2015 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent...
Elite Pharmaceuticals Awarded Second Canadian Patent for Abuse Deterrent Drug Formulation
16 déc. 2014 08h38 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the continued expansion of Elite's intellectual property...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
03 déc. 2014 09h55 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals Releases Positive Top Line Human Abuse Liability Data for ELI-200, an Opioid Abuse Deterrent Product
09 sept. 2014 07h00 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today reported top line results from a Human Abuse Liability (HAL) study for the...
Elite Pharmaceuticals to Present at the 16th Annual Rodman & Renshaw Global Investment Conference in New York City September 8-10th
03 sept. 2014 13h47 HE
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. (OTCBB:ELTP) a specialty pharmaceutical company developing a pipeline of pharmacological abuse deterrent opioids with...
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2015
14 août 2014 16h14 HE
|
Elite Pharmaceuticals, Inc.
Revenues Increase by 61%, Product Development on Schedule
Conference Call Scheduled for Monday, August 18th at 11:00 AM EDT
NORTHVALE, N.J., Aug. 14, 2014 (GLOBE NEWSWIRE) -- Elite...